Diagnosis and treatment of patients with thyroid cancer

American Health and Drug Benefits

Volumn 8, Issue 1, 2015, Pages 30-38

  Nguyen, Quang T ^a   Lee, Eun Joo ^a   Huang, Melinda Gingman ^a   Park, Young In ^a   Khullar, Aashish ^b   Plodkowski, Raymond A ^c  

^a TOURO UNIVERSITY NEVADA   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^c SCRIPPS GREEN HOSPITAL   (United States)

Author keywords

Endocrine system; Fine needle aspiration biopsy; Radioactive iodine; Thyroid cancer; Thyroidectomy; Tyrosine kinase inhibitors

Indexed keywords

B RAF KINASE; CABOZANTINIB; CARBOPLATIN; PACLITAXEL; RADIOACTIVE IODINE; SORAFENIB; THYROTROPIN; THYROTROPIN RECEPTOR; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ABLATION THERAPY; ALOPECIA; ANAPLASTIC THYROID CANCER; BLEEDING; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; EARLY DIAGNOSIS; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FINE NEEDLE ASPIRATION BIOPSY; FISTULA; HAND FOOT SYNDROME; HYPERTENSION; LYMPH NODE METASTASIS; MOLECULARLY TARGETED THERAPY; NAUSEA; NECK DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RASH; RESPIRATORY FAILURE; REVIEW; SEPSIS; SUBTOTAL THYROIDECTOMY; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TRACHEOSTOMY;

EID: 84923380386     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. National Cancer Institute. A snapshot of thyroid cancer. November 5, 2014. www. cancer. gov/researchandfunding/snapshots/thyroid. Accessed January 12, 2015.
2. National Cancer Institute. SEER stat fact sheets: thyroid cancer. http://seer. cancer. gov/statfacts/html/thyro. html. Accessed January 12, 2015.
3. American Cancer Society. Thyroid cancer: what are the key statistics about thyroid cancer? Revised January 12, 2015. www. cancer. org/cancer/thyroidcancer/detailedguide/thyroid-cancer-key-statistics. Accessed January 12, 2015.
4. Knox MA. Thyroid nodules. Am Fam Physician. 2013; 88: 193-196.
5. Cooper DS, Doherty GM, Haugen BR, et al; for the American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: the American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2009; 19: 1167-1214. Errata in: Thyroid. 2010; 20: 674-675; Thyroid. 2010; 20: 942.
6. Corso C, Gomez X, Sanabria A, et al. Total thyroidectomy versus hemithyroidectomy for patients with follicular neoplasm. A cost-utility analysis. Int J Surg. 2014; 12: 837-842.
7. Welker MJ, Orlov D. Thyroid nodules. Am Fam Physician. 2003; 67: 559-566.
8. National Cancer Institute. Thyroid cancer treatment (PDQ). Updated July 11, 2014. http://cancer. gov/cancertopics/pdq/treatment/thyroid/HealthProfessional. Accessed January 12, 2015.
9. MedlinePlus. Thyroid cancer. Updated March 23, 2014. www. nlm. nih. gov/medlineplus/ency/article/001213. htm. Accessed January 12, 2015.
10. Nikiforov YE, Yip L, Nikiforova MN. New strategies in diagnosing cancer in thyroid nodules: impact of molecular markers. Clin Cancer Res. 2013; 19: 2283-2288.
11. Fitzgerald PA. Thyroid cancer. In: Papadakis MA, McPhee SJ, eds. Current Medical Diagnosis & Treatment 2013. 52nd ed. US: McGraw-Hill Companies; 2013: 1126-1134.
12. Tuttle RM. Differentiated thyroid cancer: overview of management. UpToDate. www. uptodate. com/contents/differentiated-thyroid-cancer-overview-of-management?source=search_result&search=Differentiated+thyroid+cancer% 3A+overview+of+management&selectedTitle=1~150#H27. Accessed January 29, 2015.
13. Nixon IJ, Ganly I, Shah JP. Thyroid cancer: surgery for the primary tumor. Oral Oncol. 2013; 49: 654-658.
14. Lucchini R, Monacelli M, Santoprete S, et al. Differentiated thyroid tumors: surgical indications. G Chir. 2013; 34: 153-157.
15. Rudolph N, Dominguez C, Beaulieu A, et al. The morbidity of reoperative surgery for recurrent benign nodular goitre: impact of previous unilateral thyroid lobectomy versus subtotal thyroidectomy. J Thyroid Res. 2014; 2014: 231857.
16. Leiker AJ, Yen TW, Cheung K, et al. Cost analysis of thyroid lobectomy and intraoperative frozen section versus total thyroidectomy in patients with a cytologic diagnosis of "suspicious for papillary thyroid cancer." Surgery. 2013; 154: 1307-1313; discussion 1313-1314.
17. Khavanin N, Mlodinow A, Kim JYS, et al. Predictors of 30-day readmission after outpatient thyroidectomy: an analysis of the 2011 NSQIP data set. Am J Otolaryngol. 2014; 35: 332-339.
18. Terris DJ, Snyder S, Carneiro-Pla D, et al; for the American Thyroid Association Surgical Affairs Committee Writing Task Force. American Thyroid Association statement on outpatient thyroidectomy. Thyroid. 2013; 23: 1193-1202.
19. Christou N, Mathonnet M. Complications after total thyroidectomy. J Visc Surg. 2013; 150: 249-256.
20. Shore S, Waghorn AJW. Thyroidectomy. Surgery (Oxf). 2011; 29: 446-450.
21. Vaisman F, Shaha A, Fish S, Tuttle RM. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf). 2011; 75: 112-119.
22. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007; 246: 375-381; discussion 381-384.
23. Wartofsky L, Van Nostrand D. Radioiodine treatment of well-differentiated thyroid cancer. Endocrine. 2012; 42: 506-513.
24. Valachis A, Nearchou A. High versus low radioiodine activity in patients with differentiated thyroid cancer: a meta-analysis. Acta Oncol. 2013; 52: 1055-1061.
25. Schlumberger M, Catargi B, Borget I, et al; for the Tumeurs de la Thyroide Refractaires Network for the Essai Stimulation Ablation Equivalence Trial. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012; 366: 1663-1673.
26. Luster M, Clarke SE, Dietlein M, et al; for the European Association of Nuclear Medicine (EANM). Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008; 35: 1941-1959.
27. Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012; 366: 1674-1685.
28. Tuttle RM. Differentiated thyroid cancer: radioiodine treatment. UpTo-Date. Updated July 15, 2014. www. uptodate. com/contents/differentiated-thyroid-cancer-radioiodine-treatment. Accessed January 12, 2015.
29. Iyer NG, Morris LGT, Tuttle RM, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011; 117: 4439-4446.
30. Tala H, Robbins R, Fagin JA, et al. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab. 2011; 96: 2105-2111.
31. Grenfell S, Roos D, Rijken J, et al. Comparison of effective I-131 half-life between thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone for thyroid cancer: a retrospective study. J Med Imaging Radiat Oncol. 2014 Oct 6. Epub ahead of print.
32. Pak K, Cheon GJ, Kang KW, et al. The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trials. J Korean Med Sci. 2014; 29: 811-817.
33. Tu J, Wang S, Huo Z, et al. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis. Radiother Oncol. 2014; 110: 25-30.
34. Smit J. Tyrosine kinase inhibitors in thyroid cancer. Endocr Abstracts. 2010; 22. Abstract S5. 3.
35. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003; 95: 625-627.
36. Henderson YC, Shellenberger TD, Williams MD, et al. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res. 2009; 15: 485-491.
37. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, et al. The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer. 2006; 13: 257-269.
38. Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab. 2010; 95: 2588-2595.
39. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012; 30: 134-141. Erratum in: J Clin Oncol. 2013; 31: 3049.
40. Exelixis. FDA approves Cometriq (cabozantinib) for treatment of progressive, metastatic medullary thyroid cancer. November 29, 2012. http://exelixis. com/investors-media/press-releases. Accessed January 21, 2015.
41. Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013; 31: 3639-3646. Erratum in: J Clin Oncol. 2014; 32: 1864.
42. Brose MS, Nutting CM, Jarzab B, et al; for the DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014; 384: 319-328.
43. Nexavar (sorafenib) tablets [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; November 2013.
44. Brose MS, Nutting CM, Sherman SI, et al. Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer. 2011; 11: 349.